GEN - Genetic Engineering & Biotech NewsOriginal article
Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders
Phase 2positiveBrenipatidePositive
AI Analysis
Summary
Lilly's GIP/GLP-1 receptor agonist brenipatide demonstrated favorable pharmacokinetic properties in early clinical evaluation, with a dose-dependent half-life ranging from 9.08 to 12.5 days for the treatment of substance and psychiatric disorders.
Clinical Trial Data
Phase
2
Outcome Details
Demonstrated mean half-life of 9.08-12.5 days with dose-dependent pharmacokinetics; longest half-life observed at 4.5 mg dose
Importance:5/10
Sentiment:
0.60
GIP/GLP-1 agonistearly clinical datapharmacokineticsCNS indicationsubstance use disorderpsychiatric disorder
Related Companies
Read the original article
Published by GEN - Genetic Engineering & Biotech News on September 19, 2026 5:31 PM